secwatch.observer — SEC 8-K summary
======================================

Issuer:     Twist Bioscience Corp (TWST)
CIK:        0001581280
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001628280-24-019999
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Twist Bioscience reports record Q2 revenue $75.3M (+25% YoY), raises FY2024 guidance
--------------------------------------------------------------------------------

- Record revenue $75.3M (+25% YoY); orders $93.2M (+45% YoY).
- Net loss $45.5M ($0.79/sh) vs $59.2M ($1.04) YoY; adjusted EBITDA -$26.8M.
- Gross margin improved to 41% from 31%; FY2024 revenue guidance raised to $300-304M, gross margin 41.5-42.0%.
- Cash burn improved: net cash from ops -$42.4M H1FY24 vs -$98.4M; cash $293.3M.
- NGS revenue $40.8M (+41% YoY), SynBio $29.8M (+23%), Biopharma $4.7M (-33%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1581280/000162828024019999/0001628280-24-019999-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1581280/000162828024019999/twist-20240502.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-019999

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer